Marginal zone lymphomas (MZLs) are a group of indolent (slow-growing) B-cell non-Hodgkin lymphomas (NHLs), that develop in a part of the lymph node (a small bean-shaped structure that helps the body fight disease; Figure 1) tissue called the “marginal zone”.

MZL is the third most-common indolent lymphoma and accounts for approximately 5% to 10% of all NHLs. The number of new cases of MZL increases with age, but the average age at diagnosis depends on the type of MZL (see below).

Symptoms depend on the tumor location (where the tumor is located in the body) and the extent (the spread of the cancer) of the disease. The most common symptoms associated with all forms of the disease include:

- Swollen lymph nodes (a lump that you can see or feel)
- Tiredness
- Skin rash
- Chest or abdominal pain
- Night sweats
- Weight loss
- Fever

SUBTYPES OF MZL

Mucosa-associated lymphoid tissue (MALT) lymphoma or extranodal MZL is the most common form of MZL (61% of all MZL cases). This type of MZL affects tissues outside the lymph nodes (extranodal tissues), like the mucosa (inner lining) of some internal organs and body cavities. Listed below are the organs where MALT lymphomas are found:

- Stomach (called gastric MALT)
- Small intestine, salivary glands, thyroid, breast, around the eye (ocular adnexal lymphoma [OAL]), lung, and skin (called non-gastric MALT)

MALT lymphomas often appear as a result of chronic inflammation (slow long-term body response to infection lasting for prolonged periods of several months to years) caused by infections (with bacteria) or autoimmune conditions (the body’s immune system starts attacking its own healthy cells) such as Hashimoto’s thyroiditis or Sjögren’s syndrome. In some patients, this might increase the risk of these conditions developing into lymphoma cells. However, most patients with these autoimmune diseases will not develop MALT.
The bacteria that are known to cause MALT lymphoma include:

- Helicobacter pylori, which causes chronic inflammation of the stomach and gastritis
- Chlamydia psittaci, which can cause orbital MALT lymphoma
- Campylobacter jejuni, which causes Mediterranean abdominal lymphoma (or immunoproliferative small intestinal disease), often originated in the abdomen. It is a type of MALT lymphoma that affects young adults in eastern Mediterranean countries

Nodal MZL is a rare type of MZL [30% of all MZL cases] that occurs within the lymph nodes.

Splenic MZL is the rarest form of MZL [9% of all cases] and occurs most often in the spleen, blood, and bone marrow. It has been associated with hepatitis C virus (HCV) infection.

**TREATMENT OPTIONS**

When patients show no symptoms, doctors may decide to monitor the patient without treating the disease. This approach is called active surveillance, or “watchful waiting”. In this case, patients overall health and disease are monitored through regular check-ups that may include laboratory tests (like a complete blood cell count) and imaging tests (such as computer tomography [CT] scans). To know more about active surveillance, view the Active Surveillance fact sheet on the Lymphoma Research Foundation’s [LRF’s] website at lymphoma.org/publications.

Treatment is started if the patient begins to develop lymphoma-related symptoms or there are signs that the disease is progressing [cancer is growing and/or spreading]. Treatment selection for a patient with MZL depends on:

- The MZL subtype, stage [the size of the cancer and whether it has spread], and location [where in the body the tumor is located]
- Patient’s age and overall health
- MZL signs or symptoms

**GASTRIC MALT LYMPHOMA**

Since gastric MALT lymphoma is often the result of an infection with Helicobacter pylori, the initial treatment combines therapy with two antibiotics [drugs that fight bacterial infections] and one proton pump inhibitor (PPI; drugs that reduce the amount of acid in the stomach), typically given for two weeks. PPIs help to prevent or heal stomach ulcers [sores on the walls of the stomach]. In about 80% of cases, gastric MALT lymphomas go away after antibiotic and PPI treatment, although this may take several months.

Most gastric MALT lymphomas are low-grade lesions that grow slowly and do not commonly spread to other places in the body. If the lymphoma relapses [returns after treatment] or becomes refractory [does not respond to treatment] after antibiotic therapy, there are many additional treatment options available. This includes another round of antibiotic treatment, radiation, and immunotherapy [drugs that use the body’s immune system to fight cancer] with monoclonal antibodies targeting CD20, such as rituximab [Rituxan], alone or in combination with chemotherapy [chemoimmunotherapy]. Common initial chemoimmunotherapy regimens are:

- Bendamustine [Treanda] plus rituximab (BR)
- R-CHOP [rituximab [Rituxan], cyclophosphamide, doxorubicin, vincristine, and prednisone]
- R-CVP [rituximab [Rituxan], cyclophosphamide, vincristine, and prednisone]

Patients seeking information about immunotherapy should view the Immunotherapy and Other Targeted Therapies fact sheet on LRF’s website [lymphoma.org/publications].

**NON-GASTRIC MALT LYMPHOMAS**

Non-gastric MALT lymphomas can appear throughout the body. Therefore, treatment is usually based on the exact location of the lymphoma and how far it has spread. For ocular adnexal lymphoma (OAL), radiation therapy with or without antibiotic therapy is usually very effective, and patients may achieve durable remission [no signs or symptoms of disease for a long time]. The antibiotic doxycycline has been shown to be effective in MALT that affects the area around the eye, especially in certain areas of the world where infection with Chlamydia psittaci is commonly associated with OAL. In localized cases, treatment usually includes radiation therapy. In rare cases where radiation is not feasible, surgery can be used as an alternative.

More advanced disease is usually treated with immunotherapy such as the monoclonal antibody rituximab [Rituxan], with or without chemotherapy [as described above].

**NODAL MZL**

Because nodal MZL is most often a slow-growing disease, physicians may recommend an active surveillance approach until symptoms appear. When treatment is necessary, options include radiation therapy, chemotherapy and/or immunotherapy, and other treatments commonly used in other types of slow-growing lymphomas, such as follicular lymphoma.

**SPLENIC MZL**

Treatment is not always immediately necessary for splenic MZL, but when a treatment is needed, several options exist. Some patients may receive a surgery called splenectomy [removal of the spleen] while other patients may be given rituximab [Rituxan] with or without chemotherapy. When the splenic MZL is associated with HCV infection, treatment of the infection might cure the lymphoma.

New treatments for all subtypes have been recently approved for relapsed disease. Lenalidomide [Revlimid], is an immunomodulatory [a drug that either activates or slows down the immune system response] oral medication that has been approved by the FDA for the treatment of patients with MZL who have received at least one prior therapy, and it is used in combination with rituximab [Rituxan], often referred to as R2 (R-squared). Recently, another BTK inhibitor called zanubrutinib [Brukinsa] was approved for use in adult patients with relapsed or refractory MZL after at least one prior anti-CD20-based regimen.
For all subtypes, biosimilar therapies [drugs that are similar to an existing biological therapy [reference drug] but may cost less than the reference drug] may be an option for patients who are taking rituximab (Rituxan). These include rituximab-abbs and rituximab-pvvr. For more information, patients should view the Biosimilars fact sheet on LRF’s website at lymphoma.org/publications and talk to their physician.

It is critical to remember that today’s scientific research is always evolving. Treatment options may change as new treatments are discovered and current treatments are improved. Therefore, it is important that patients check with their physician or with the LRF for any treatment updates that may have recently appeared. It is also very important that all patients consult with a specialist to clear up any questions.

TREATMENTS UNDER INVESTIGATION

Many new treatments [also referred to as investigational drugs] and treatment combinations [two or more treatments given at the same time] are currently being tested in clinical trials for patients with newly diagnosed and relapsed or refractory MZL. Results from these clinical trials may improve or change the current standard of care [the proper treatment that is widely used by healthcare professionals and accepted by medical experts]. Table 1 (below) lists some of these investigational drugs that can be accessed through a clinical trial. For more information on clinical trials, view the Understanding Clinical Trials publication on the LRF’s website at lymphoma.org/publications.

Table 1. Investigational Drugs for Newly Diagnosed and Relapsed or Refractory Marginal Zone Lymphoma

<table>
<thead>
<tr>
<th>Agent (Drug)</th>
<th>Class (Type of Treatment)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acalabrutinib (Calquence)</td>
<td>Targeted therapy; BTK inhibitor</td>
</tr>
<tr>
<td>Axicabtagene cileoleucel (Yescarta)</td>
<td>CAR T-cell therapy; anti-CD19</td>
</tr>
<tr>
<td>Bortezomib (Velcade)</td>
<td>Targeted therapy; proteasome inhibitor</td>
</tr>
<tr>
<td>HMPL-689</td>
<td>Targeted therapy; PI3Kδ inhibitor</td>
</tr>
<tr>
<td>Idelalisib (Zydelig)</td>
<td>Targeted therapy; PI3Kδ inhibitor</td>
</tr>
<tr>
<td>Ixazomib (Ninlaro)</td>
<td>Targeted therapy; proteasome inhibitor</td>
</tr>
<tr>
<td>Mosunetuzumab (Lunsumio)</td>
<td>Immunotherapy; bispecific antibody</td>
</tr>
<tr>
<td>Nivolumab (Opdivo)</td>
<td>Immune checkpoint inhibitor; anti-PD-1 receptor</td>
</tr>
<tr>
<td>Obinutuzumab (Gazyva)</td>
<td>Immunotherapy; monoclonal antibody, anti-CD20</td>
</tr>
<tr>
<td>Parsaclisib (IBI376)</td>
<td>Targeted therapy; PI3Kδ inhibitor</td>
</tr>
<tr>
<td>Pembrolizumab (Keytruda)</td>
<td>Immune checkpoint inhibitor; anti-PD-1 receptor</td>
</tr>
<tr>
<td>Polatuzumab vedotin (Polivy)</td>
<td>Immunotherapy; antibody-drug conjugate</td>
</tr>
<tr>
<td>Tafasitamab (Monjuvi)</td>
<td>Immunotherapy; monoclonal antibody, anti-CD19</td>
</tr>
<tr>
<td>Venetoclax (Venclexta)</td>
<td>Targeted therapy; BCL2 inhibitor</td>
</tr>
<tr>
<td>Zandelisib (ME-401)</td>
<td>Targeted therapy; PI3Kδ inhibitor</td>
</tr>
</tbody>
</table>

BCL2, B-cell lymphoma 2 protein; BTK, Bruton’s tyrosine kinase; CAR, chimeric antigen receptor; CD, cluster of differentiation; PD-1, programmed cell death protein 1; PI3K, phosphoinositide 3-kinase.

CLINICAL TRIALS

Clinical trials are crucial in identifying effective drugs and optimal treatment doses for patients with lymphoma. Patients interested in participating in a clinical trial should view the Understanding Clinical Trials fact sheet on LRF’s website (lymphoma.org/publications), talk to their physician, or contact the LRF Helpline for an individualized clinical trial search by calling (800) 500-9976 or emailing helpline@lymphoma.org.

FOLLOW-UP

Patients with lymphoma should have regular visits to their physician. During these visits, medical tests [such as blood tests, computed tomography (CT) scans, and positron emission tomography (PET) scans] may be required to evaluate the need for additional treatment.

Some treatments can cause long-term side effects [occur during treatment and continue for months or years] or late side effects [appear only months, years, or decades after treatment has ended]. These can vary depending on the following factors:

- Duration of treatment [how long the treatment lasted]
- Frequency of treatment [how often the treatment was administered]
- Type of treatment given
- Patient’s age and gender
- Patient’s overall health at the time of treatment

A physician and their care team will check for these side effects during follow-up care. Visits may become less frequent the longer the patient stays in remission.

Patients and their caregivers are encouraged to keep copies of all medical records. This includes test results as well as information on the type, amount, and duration of all treatments received. Medical records are important for keeping track of any side effects resulting from treatment or potential disease recurrences. LRF’s award-winning Focus on Lymphoma mobile app can help patients manage this documentation.
LYMPHOMA CARE PLAN AND PATIENT EDUCATION PROGRAMS

Keeping your information in one location can help you feel more organized and in control. This also makes it easier to find information pertaining to your care and saves valuable time. LRF’s Lymphoma Care Plan document organizes information on your health care team, treatment regimen, and follow-up care. You can also keep track of health screenings and any symptoms you experience to discuss with your health care provider during future appointments. The Lymphoma Care Plan document can be accessed by visiting lymphoma.org/publications. LRF also offers a variety of educational activities, including live meetings and webinars, for individuals looking to learn directly from lymphoma experts. To view our schedule of upcoming programs, please visit lymphoma.org/programs.

LRF Helpline

The LRF Helpline staff are available to answer your general questions about lymphoma and treatment information, as well as provide individual support and referrals to you and your loved ones. Callers may request the services of a language interpreter. LRF also offers a one-to-one peer support program called the Lymphoma Support Network and clinical trials information through our Clinical Trials Information Service. For more information about any of these resources, visit our website at lymphoma.org, or contact the LRF Helpline at (800) 500-9976 or helpline@lymphoma.org.

Para información en Español, por favor visite lymphoma.org/es. (For Information in Spanish, please visit lymphoma.org/es).

LRF FOCUS ON LYMPHOMA MOBILE APP

Focus on Lymphoma is the first app to provide patients and their caregivers with tailored content based on lymphoma subtype and actionable tools to better manage diagnosis and treatment. It provides convenient and comprehensive lymphoma management in one secure and easy-to-navigate app, no matter where you are on the care continuum. Get the right information first, with resources from the entire Lymphoma Research Foundation content library, use unique tracking and reminder tools, and connect with a community of specialists and patients. To learn more about this resource, visit our website at lymphoma.org/mobileapp, or contact the LRF Helpline at 800-500-9976 or helpline@lymphoma.org.

Contact LRF:
Helpline: (800) 500-9976
Email: helpline@lymphoma.org
www.lymphoma.org

Supported through grants from: Bristol Myers Squibb, Genentech, Biogen

The Understanding Lymphoma fact sheet series is published by the Lymphoma Research Foundation (LRF) for the purpose of informing and educating readers. Facts and statistics were obtained using published information, including data from the Surveillance, Epidemiology, and End Results (SEER) Program. Because each person’s body and response to treatment is different, no individual should self-diagnose or embark upon any course of medical treatment without first consulting with his or her physician. The medical reviewer, the medical reviewer’s institution, and LRF are not responsible for the medical care or treatment of any individual.

© 2023 Lymphoma Research Foundation

Last updated 2023